Elacestrant: a new FDA-approved SERD for the treatment of breast cancer.

Published in: Medical oncology (Northwood, London, England) (2023)

Elacestrant (RAD-1901), a selective estrogen receptor degrader, was approved by USFDA on January 27, 2023, for the treatment of breast cancer. It has been developed by Menarini Group under the brand name Orserdu®. Elacestrant showed anticancer activity both in vitro and in vivo in ER+ HER2-positive breast cancer models. The present review delebrates the development stages of Elacestrant, with its medicinal chemistry, synthesis, mechanism of action, and pharmacokinetic studies. Clinical data and safety profile has also been discussed, including data from randomized trials.

Keyphrases

estrogen receptor
positive breast cancer
dna damage
oxidative stress
big data
combination therapy
endoplasmic reticulum
drug administration
smoking cessation
replacement therapy
childhood cancer